EU clears six Mounjaro KwikPen strengths for multidose tirzepatide pen

The European Commission authorized six additional Mounjaro strengths for a multidose pre-filled pen in a decision dated April 19, 2024, according to the European Medicines Agency's procedural record for the drug ^[1]. The decision came after a favorable opinion issued on Feb. 22, 2024 ^[1].

Mounjaro's active ingredient is tirzepatide. The extension application, listed as X/0015, adds the following strengths of "Mounjaro solution for injection in pre-filled pen (KwikPen), multidose": 2.5 mg/dose (4.17 mg/ml), 5 mg/dose (8.33 mg/ml), 7.5 mg/dose (12.5 mg/ml), 10 mg/dose (16.67 mg/ml), 12.5 mg/dose (20.83 mg/ml) and 15 mg/dose (25 mg/ml) ^[1].

The legal basis for the filing was "change or addition of a new strength/potency." The authorization updated the Summary of Product Characteristics, Annex II, the labelling and the package leaflet ^[1].

What the extension covers

A multidose pen holds more than one dose in a single device. The EU record does not list how many doses are in each KwikPen, what the needle or storage requirements are, or how the pens will be priced ^[1].

Six strengths mean every step of the dose range appears in the pen format, from 2.5 mg up to 15 mg per dose ^[1]. That range matters because tirzepatide is typically started low and increased over time, so a single device type can cover the whole scale.

Mounjaro's European authorization has been widened in other ways as well, per the same record. In a procedure listed as II/0007, the EU added a chronic weight management indication — for adults with a body mass index of at least 30, or at least 27 with a weight-related condition — based on the SURMOUNT-1 trial and five supportive SURPASS trials. The opinion was issued Nov. 9, 2023, and the Commission decision on Dec. 11, 2023 ^[1]. In the EU, both the diabetes and weight-management uses sit under the Mounjaro name.

Why it matters for patients

For people in Europe who use tirzepatide, the practical difference is the device rather than the drug. The molecule, the doses and the once-weekly schedule described in the record are unchanged; what is new is that all six strengths are authorized in a multidose pen ^[1].

For US readers, this decision has no direct effect. It applies to the European market only ^[1]. Whether a multidose pen for tirzepatide will be sold in the United States, and on what timeline, has not been reported in this record ^[1]. In the US, tirzepatide is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management; the EU record does not discuss US brand names or US approvals.

Nothing in the record suggests the approved doses themselves changed, and the EU regulator has not published a new safety finding tied to this extension. The safety-related entries on the same pages are separate procedures, including periodic safety assessments of tirzepatide ^[1].

What happens next

Later entries in the same official record show the EU label continued to change after the pen approval. A periodic safety update assessment for tirzepatide was decided on Feb. 14, 2025 ^[1]. A variation to add an obstructive sleep apnea indication, based on two randomized, placebo-controlled trials in adults with moderate-to-severe OSA and obesity, drew an opinion on Dec. 12, 2024, and a Commission decision on Feb. 14, 2025 ^[1]. Another entry, listed as II/0038, covers a label update based on final results from the SUMMIT trial in people with heart failure with preserved ejection fraction and obesity, with an opinion dated Jan. 29, 2026 ^[1].

Those entries describe European regulatory steps. Timelines for US versions of the same changes are not part of this record ^[1].